Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 92d5098b3d82cf8b-LAX IP: 118.31.43.22 UTC time: 2025-04-08T22:00:23+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4

Comments (0)

No login
gif